Emergent BioSolutions Inc. — Director's Dealing 2019

Mar 1, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-02-26

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-26	Common Stock	S	10369	$59.65	Disposed	1478306	Direct
2019-02-26	Common Stock	M	6430	—	Acquired	1484736	Direct
2019-02-26	Common Stock	F	1566	$61.01	Disposed	1483170	Direct
2019-02-27	Common Stock	S	10369	$58.24	Disposed	1472801	Direct
2019-02-27	Common Stock	M	9794	—	Acquired	1482595	Direct
2019-02-27	Common Stock	F	2486	$57.98	Disposed	1480109	Direct
2019-02-28	Common Stock	S	6987	$58.47	Disposed	1473122	Direct
2019-02-28	Common Stock	M	9722	—	Acquired	1482844	Direct
2019-02-28	Common Stock	F	3826	$58.71	Disposed	1479018	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-26	Restricted Stock Units	$	M	6430	Disposed		Common Stock (6430)	Direct
2019-02-26	Restricted Stock Units	$	A	18029	Acquired		Common Stock (18029)	Direct
2019-02-26	Stock Options (Right to Buy)	$61.01	A	36053	Acquired	2026-02-25	Common Stock (36053)	Direct
2019-02-27	Restricted Stock Units	$	M	9794	Disposed		Common Stock (9794)	Direct
2019-02-28	Restricted Stock Units	$	M	9722	Disposed		Common Stock (9722)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4344250	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.40 to $61.21.

F3: Restricted stock units convert into common stock on a one-for-one basis.

F4: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.96 to $59.08.

F5: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $59.25.

F6: Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F7: Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F8: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

F9: On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

F10: On February 26, 2019, Mr. El-Hibri was granted 36,053 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

F11: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

F12: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.